WHO Solidarity Trial

WHO Solidarity Trial
Name	Solidarity Trial
Organizer	World Health Organization
Start date	2020
Type	International, adaptive, randomized, open-label
Participants	>12,000 patients across >30 countries
Main objective	Evaluate repurposed antiviral and immunomodulatory therapies for COVID-19
Registration	WHO clinical trial platforms

WHO Solidarity Trial The Solidarity Trial was a large, pragmatic, international clinical trial organized by the World Health Organization to evaluate candidate therapeutics during the COVID-19 pandemic. Designed for rapid, adaptive evaluation across diverse health systems, the study enrolled hospitalized patients in numerous countries to assess mortality, need for ventilation, and duration of hospitalization. The trial’s streamlined data collection and international collaboration sought to supply timely evidence to inform treatment guidance issued by bodies such as the United States Food and Drug Administration, European Medicines Agency, and national ministries of health.

Background

The trial emerged amid the global emergency declared by the World Health Organization in January 2020 after the outbreak in Wuhan. Early in the pandemic, repurposed drugs demonstrated in vitro activity or anecdotal clinical benefits in settings such as Italy, Spain, and New York City. Global research mobilization included initiatives like the RECOVERY (trial), the ACTT series coordinated by the National Institutes of Health, and consortia involving the Wellcome Trust and Coalition for Epidemic Preparedness Innovations. Against this backdrop, the Solidarity Trial sought to avoid duplicated small trials—an issue highlighted in discussions at the World Health Assembly and by bodies including the European Centre for Disease Prevention and Control.

Trial design and methods

The Solidarity Trial used an adaptive, open-label, randomized platform design, enabling entry and removal of treatment arms as evidence accumulated. Randomization occurred at the hospital level with simple electronic forms to minimize burden on clinicians in settings such as Brazil, India, and South Africa. Primary endpoints included in-hospital mortality and initiation of ventilation; secondary endpoints covered length of stay and safety signals. Data coordination involved the World Health Organization Clinical Trials Unit and national trial networks; ethical oversight included review by institutional review boards and national regulatory agencies like the Medicines and Healthcare products Regulatory Agency.

Interventions and treatment arms

Initial arms evaluated repurposed antiviral and immunomodulatory agents selected on the basis of preliminary laboratory or clinical rationale. Early treatment arms included remdesivir, hydroxychloroquine, lopinavir/ritonavir, and the antimalarial/complement modulator interferon beta-1a. Subsequent amendments removed or paused arms as external data—such as findings from the RECOVERY (trial) and the Adaptive COVID-19 Treatment Trial—informed equipoise. Supportive standard-of-care arms reflected contemporaneous practice in participating sites, with concurrent co-enrollment policies coordinated with trials like SOLIDARITY II and national investigator-initiated studies.

Outcomes and key results

Interim and final analyses published by the World Health Organization and collaborating investigators reported that several evaluated agents did not significantly reduce in-hospital mortality compared with standard of care. The trial found no definitive mortality benefit for hydroxychloroquine, lopinavir/ritonavir, or interferon beta-1a when used in the hospitalized population studied. Results concerning remdesivir were nuanced: while smaller randomized trials such as ACTT-1 suggested reduced time to recovery, Solidarity’s larger pragmatic analysis did not demonstrate a clear mortality reduction. These outcomes influenced clinical guidance from organizations including the United States Centers for Disease Control and Prevention, the National Health Service (England), and the World Health Organization.

Interpretation, impact, and policy response

The Solidarity Trial’s rapid, multinational evidence generation directly informed treatment recommendations and procurement decisions by public health institutions such as the Pan American Health Organization and national ministries like those of Canada and Australia. Policymakers used Solidarity data alongside results from the RECOVERY (trial), ACTT-1, and systematic reviews conducted by groups like the Cochrane Collaboration to update formularies and clinical protocols. The trial also demonstrated the feasibility of coordinated global trials during pandemics, influencing planning at organizations such as the Global Fund and the Gavi, the Vaccine Alliance for future emergency research readiness.

Criticisms and limitations

Critiques of the Solidarity Trial included concerns about the open-label design and limited collection of granular endpoints such as virologic kinetics or biomarker-driven subgroup analyses—issues debated at forums including the World Health Assembly and panels convened by the European Medicines Agency. Observers noted heterogeneity across participating sites in standards of care, concomitant therapies, and timing of intervention relative to symptom onset, similar to challenges documented in multicenter trials like RECOVERY (trial). Additionally, some commentators argued that the pragmatic approach risked reduced sensitivity to detect modest treatment effects compared with placebo-controlled, double-blind trials conducted by entities such as the National Institutes of Health. Despite these limitations, the trial’s scale and speed provided robust, policy-relevant evidence that reshaped therapeutic strategies during the COVID-19 pandemic.

Category:Clinical trials